Table 2.
Baseline Demographic and Disease Characteristics by Diagnostic Criteria
| VOD/SOS Diagnosed by | ||||
|---|---|---|---|---|
| Characteristic | All VOD/SOS Criteria (N = 803) | Baltimore Criteria (n = 449) | Modified Seattle Criteria (n = 331) | Biopsy (n = 23) |
| Age at HCT, yr, median (range) | 12 (<1-77) | 14 (<1-77) | 9 (<1-71) | 43 (<1-68) |
| Age class at HCT, n (%) | ||||
| ≤16 yr | 466 (58) | 251 (56) | 211 (64) | 4 (17) |
| >16 yr | 337 (42) | 198 (44) | 120 (36) | 19 (83) |
| Primary disease in >5% of all patients, n (%) | ||||
| Acute myelogenous leukemia | 203 (25) | 114 (25) | 75 (23) | 14 (61) |
| Acute lymphoblastic leukemia | 152 (19) | 95 (21) | 56 (17) | 1 (4) |
| Myelodysplastic syndrome | 40 (5) | 23 (5) | 15 (5) | 2 (9) |
| Neuroblastoma | 101 (13) | 42 (9) | 59 (18) | 0 |
| Graft-versus-host disease prophylaxis, n (%) | ||||
| None | 160 (20) | 78 (17) | 82 (25) | 0 |
| Tacrolimus | 396 (49) | 205 (46) | 174 (53) | 17 (74) |
| Methotrexate | 263 (33) | 130 (29) | 121 (37) | 12 (52) |
| Cyclosporine | 209 (26) | 145 (32) | 64 (19) | 0 |
| Sirolimus | 61 (8) | 34 (8) | 20 (6) | 7 (30) |
| Other (not specified) | 294 (37) | 183 (41) | 104 (31) | 7 (30) |
| Type of HCT, n (%) | ||||
| Allogenic | 660 (82) | 379 (84) | 259 (78) | 22 (96) |
| Autogenous | 141 (18) | 69 (15) | 71 (21) | 1 (4) |
| Unknown | 2 (<1) | 1 (<1) | 1 (<1) | 0 |
| MOD present, n (%) | 352 (44) | 226 (50) | 112 (34) | 14 (61) |